Newly developed retatrutide, a combined-action treatment targeting simultaneously GLP-1 and GIP receptors, is generating considerable interest within the weight loss community. Initial clinical trials have revealed significant decreases in body mass and gains in health markers for patients with excess weight . Scientists believe this novel appr… Read More